Albemarle is poised for growth as lithium demand rebounds, with supply cuts stabilizing prices and setting up a bullish multi-year trend. Technical analysis shows ALB is above its 30-week EMA with both short- and long-term momentum indicators signaling a strong upward trend. Volume patterns indicate institutional buying support since April 2025, reinforcing the positive technical outlook for ALB shares.

Caterpillar lifts its 2025 tariff impact forecast to $1.8B, while expecting margins near the bottom of its target range.

ServiceNow (NOW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CYH benefits from rising occupancy, higher revenue per admission, and business streamlining, supporting its case as a stock to retain in your portfolio.

WhatsApp said on Friday that it fixed a security bug in its iOS and Mac apps that was being used to stealthily hack into the Apple devices of “specific targeted users.”

Does robust liquidity and a strong outlook provide an edge to NLY over ABR? Let us find out which mREIT is more compelling.

GS and EVR are focusing on strengthening their IB businesses. Read on to know which stock presents a better opportunity.

Dell Technologies' second-quarter fiscal 2026 results reflect strong AI-driven growth and an expanding backlog.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

Six outlier inflow signals since 2024 position Nextracker, Inc. (NXT) well for more Big Money support.

Alphabet's Google is set to face a modest EU antitrust fine in the coming weeks for allegedly anti-competitive practices in its adtech business, three people with direct knowledge of the matter said.

Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.

Bally's aggressive expansion and asset acquisitions have led to high leverage and operational challenges, despite some recent deleveraging from the iGaming sale. The iGaming divestiture reduced debt but left Bally's with a still-high Debt/EBITDA ratio and an expensive EV/EBITDA multiple, far above peers. Massive upcoming projects in Chicago and the Bronx risk further debt accumulation or shareholder dilution, raising doubts about sustainable growth.

BBWI posts Q2 sales growth and margin gains, raises the lower end of the FY25 adjusted EPS guidance and boosts buybacks to $400M.

BURL posts strong Q2 results with double-digit earnings growth, higher sales, margin gains and an upbeat fiscal 2025 outlook.

India's economy grew at an annual rate of 7.8% in the quarter ending June, topping economists' expectations of 6.7% (Reuters poll), as quoted on CNBC.

FORT WORTH, Texas, Aug. 29, 2025 (GLOBE NEWSWIRE) -- SEGG Media Corporation (NASDAQ: SEGG, LTRYW) (“SEGG Media” or the “Company”), a sports, entertainment and gaming conglomerate that owns Sports.com, Concerts.com, and Lottery.com, today announced the launch of its newly redesigned corporate website, seggmediacorp.com, a dynamic digital hub that signals the completion of the Company's turnaround and the beginning of its next phase of aggressive growth.

Companies also announce $250,000 research contribution and certification of more than 1,900 GameSense Advisors LAS VEGAS , Aug. 29, 2025 /PRNewswire/ -- MGM Resorts International (NYSE: MGM) ("MGM Resorts" or the "Company") and BetMGM announced today that they are once again partnering with the American Gaming Association (AGA) to promote Responsible Gaming Education Month (RGEM 2025) this September. For the third consecutive year, GameSense® messaging will appear at select NFL stadiums on LED ribbons—including one new venue this upcoming football season.

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's single-arm, Phase 1/2 trial of darovasertib in combination with crizotinib in first-line metastatic uveal melanoma (mUM) was accepted for an oral presentation at the 2025 Society for Melanoma Research Congress (SMR), taking place on October 25-28 in Amsterdam.

Despite recent FDA rejections and a ~50% share price drop, I remain bullish on TLX, viewing setbacks as surmountable. Strong revenue performance and cash flow stability provide TLX with ample runway to address regulatory and developmental challenges. FDA complete response letters for Pixclara and Zircaix are based on fixable issues, not dead ends, supporting eventual approval prospects.